Antrodia for Liver Cancer: HCC Research Review

Antrodia Liver Health

6+ Anti-HCC Compounds

Antrodia camphorata produces at least six distinct compound classes with demonstrated cytotoxicity against hepatocellular carcinoma cells in laboratory studies.

Hsieh et al., Chemical Research in Toxicology, 2010

IC50: 30 microM

methyl antcinate A against Huh7 cells

STAT3 Inhibition

confirmed in vitro and in vivo

0 Human Trials

all evidence is preclinical

Hsieh et al., Chemical Research in Toxicology, 2010

View as image ↗

Hepatocellular carcinoma (HCC) accounts for approximately 75% of primary liver cancers and remains one of the leading causes of cancer death globally. Antrodia camphorata has been used in Taiwanese folk medicine for liver conditions including liver cancer, and this traditional use has generated a sustained line of preclinical research since 2005. Multiple Antrodia compounds, from triterpenoids to polysaccharides to ubiquinone derivatives, have demonstrated cytotoxicity against HCC cell lines through distinct molecular mechanisms. Some compounds also sensitize cancer cells to existing chemotherapy drugs. All of this evidence remains preclinical. No human clinical trials have tested Antrodia for liver cancer outcomes.

For broader context on Antrodia's liver-protective properties beyond cancer, see Antrodia for liver health: Taiwan's most-studied hepatoprotective mushroom. For Antrodia's activity against other cancer types, see Antrodia and cancer: comprehensive research review.

How Antrodia Targets Liver Cancer Cells

The anti-HCC research on Antrodia spans nearly two decades and involves multiple compound classes, each operating through partially distinct mechanisms. The major pathways identified so far include:

Direct apoptosis induction. Triterpenoids like antcin B, methyl antcinate A, and crude extracts trigger programmed cell death in HCC cells through mitochondrial disruption, caspase activation, and Bcl-2 family protein modulation.^[1][2]

STAT3 signaling inhibition. Antrodia mycelia extract downregulates the JAK2/STAT3 pathway, a constitutively active oncogenic signaling cascade in HCC, reducing anti-apoptotic proteins and invasion-related matrix metalloproteinases.^[3]

Cancer stem cell targeting. Both mycelial fermentation broth and isolated 4-acetylantroquinonol B inhibit cancer stem cell characteristics including self-renewal, migration, and immune evasion.^[4][5]

Chemotherapy sensitization. Antrodia extracts enhance the efficacy of sorafenib, cisplatin, and doxorubicin at lower doses than standard monotherapy.^[6][7]

For a detailed look at the specific compounds involved, see antcin compounds and anti-cancer mechanisms and Antrodia bioactive compounds: antcins, triterpenoids, and polysaccharides.

Triterpenoid-Driven Apoptosis

The earliest mechanistic work came from Hsu et al. (2005), who tested ethyl acetate extract from Antrodia fruiting bodies against HepG2 and PLC/PRF/5 hepatocellular carcinoma cell lines.^[8] The extract decreased cell growth dose-dependently in both lines. In Fas/APO-1 positive HepG2 cells, the extract increased Fas and Fas ligand expression, initiated the mitochondrial apoptotic pathway through Bcl-2 family protein regulation, and released cytochrome c with caspase-9 activation. It also suppressed NF-kappaB nuclear translocation, reducing expression of the anti-apoptotic protein Bcl-X(L).

Hsieh et al. (2010) advanced this by isolating three specific compounds: antcin A, antcin C, and methyl antcinate A (MAA).^[1] All three selectively inhibited liver cancer cell proliferation while showing minimal toxicity to normal rat hepatocytes. MAA was the most potent, with IC50 values of 52.2 microM (HepG2), 78.0 microM (Hep3B), and 30.2 microM (Huh7). The mechanism involved reactive oxygen species (ROS) generation through NADPH oxidase activation, which triggered mitochondrial translocation of cofilin and Bax, leading to cytochrome c release and caspase-2, -3, and -9 activation. Pretreatment with antioxidants N-acetyl cysteine and ascorbic acid blocked the apoptotic cascade, confirming that ROS generation is the upstream trigger.

Hsieh et al. (2011) showed that antcin B and its ester derivative methylantcinate B similarly induced HepG2 cell death through NADPH oxidase-provoked oxidative stress.^[2] Both the intrinsic (mitochondrial) and extrinsic (Fas/Fas ligand) apoptotic pathways were activated simultaneously, a dual-pathway engagement that makes resistance development theoretically more difficult for cancer cells. Diphenylamine, an NADPH oxidase inhibitor, blocked ROS production and increased cell viability, confirming the oxidative stress mechanism.

The selectivity finding from Hsieh et al. (2010) is worth emphasizing. Many cytotoxic compounds kill cancer cells but also damage healthy tissue. MAA showed a clear differential between tumor cells and normal hepatocytes. Whether this selectivity holds in whole-organism models with physiologically relevant dosing remains untested.

STAT3: A Specific Molecular Target

Zhu et al. (2018) conducted the most comprehensive in vitro and in vivo study of Antrodia against HCC, focusing on the STAT3 signaling pathway.^[3] STAT3 is constitutively activated in hepatocellular carcinoma and drives expression of anti-apoptotic proteins (Bcl-xL, Bcl-2) and invasion-promoting enzymes (MMP-2, MMP-9). It has been proposed as a chemotherapeutic target for HCC.

The ethyl acetate fraction of Antrodia mycelia extract (EEAC) reduced HepG2 and SMMC-7721 cell viability, induced apoptosis, and inhibited migration and invasion. Immunoblotting revealed EEAC downregulated both phosphorylated and total STAT3 and its upstream kinase JAK2. STAT3 downregulation occurred at the transcriptional level (reduced mRNA), while JAK2 reduction was post-transcriptional. Nuclear STAT3 levels and transcriptional activity both decreased.

Critically, when STAT3 was artificially over-activated in HCC cells, EEAC's cytotoxic effects diminished. This confirms that STAT3 suppression is a causal mechanism, not merely a downstream correlation.

In the in vivo arm, EEAC at 100 mg/kg administered orally for 18 days inhibited tumor growth in SMMC-7721 cell-bearing mice. The tumors showed increased apoptosis and suppressed JAK2/STAT3 phosphorylation, matching the in vitro data. No toxicity was observed in normal human liver-derived cells, nude mice, or rats.

Combination Therapy: Sensitizing Chemotherapy Drugs

Two studies have tested Antrodia as an adjunct to existing HCC chemotherapy, producing some of the most clinically relevant preclinical data in this field.

Wu et al. (2018) tested Antrodia extract combined with sorafenib, the first-line systemic therapy for advanced HCC.^[6] The ethanolic extract (EAC) sensitized HCC cells to low doses of sorafenib, repressing cell viability and inducing cell cycle arrest and apoptosis beyond what either agent achieved alone. The combination worked through MAP kinase modulation, cyclin protein expression changes, and cancer cell invasion inhibition. In a mouse xenograft model, the combination suppressed ectopic tumor growth with high safety margins compared to single-agent treatment.

Lin et al. (2015) tested Antrodia ethanolic extract (TCEE) in combination with cisplatin and doxorubicin, two conventional chemotherapy agents used for HCC.^[7] TCEE alone induced cell cycle arrest in Hep3B and HepJ5 cells, upregulated the cell cycle inhibitors P21 and P27, and activated caspase-3. When combined with cisplatin or doxorubicin, TCEE further enhanced tumor suppression efficiency beyond either drug alone.

These combination studies matter because they suggest Antrodia could potentially reduce the effective dose of existing drugs, which would lower side effect burden. Sorafenib causes hand-foot syndrome, diarrhea, and hypertension in many patients. A sensitizing agent that allows lower sorafenib doses while maintaining efficacy would have clear clinical value. However, this remains a hypothesis supported only by mouse data.

Cancer Stem Cells and Immune Activation

Cancer stem cells (CSCs) drive tumor recurrence and treatment resistance in HCC. Two Antrodia studies have targeted this problem from different angles.

Liu et al. (2013) tested mycelial fermentation broth (AC-MFB) and found it inhibited HCC growth without causing liver enzyme abnormalities.^[4] Beyond direct cytotoxicity, AC-MFB suppressed cancer stem cell characteristics: it inhibited endothelial cell migration and tube formation (markers of angiogenesis), and reduced production of vascular endothelial growth factor (VEGF) and hypoxia-inducible factor-1 alpha (HIF-1alpha) from HCC cells. In a syngeneic mouse tumor model, AC-MFB markedly inhibited HCC growth.

Li et al. (2019) took an immunological approach, testing 4-acetylantroquinonol B (4-AAQB), a ubiquinone derivative from Antrodia mycelia.^[5] This compound inhibited EpCAM and AFP expression in HepG2 cells (markers of liver cancer stemness), reduced beta-catenin expression, and decreased secretion of immune escape cytokines. On the immune side, 4-AAQB stimulated dendritic cell proliferation and enhanced their endocytosis of immature cells. When dendritic cells were co-cultured with EpCAM+ HepG2 cells in the presence of 4-AAQB, MHC class I and II expression increased on both cancer and immune cells, and the costimulatory molecule CD80 was upregulated on dendritic cells.

This dual action, suppressing cancer cell immune evasion while simultaneously enhancing immune cell recognition, represents a mechanism distinct from the direct cytotoxicity studies. It aligns with modern immunotherapy concepts, though far from clinical application.

Polysaccharides and Drug Delivery Innovation

Chang et al. (2015) addressed a practical challenge: Antrodia polysaccharides have demonstrated anti-cancer activity, but their large molecular size limits cellular uptake.^[9] The team nano-encapsulated Antrodia polysaccharides in chitosan-silica nanoparticles (ACE/CS) and tested them against HepG2 cells.

Both free polysaccharides and nanoencapsulated forms damaged HepG2 cell membranes and induced apoptosis. The nanoencapsulated chitosan-silica formulation achieved this at 13.2 microg/mL of polysaccharides, compared to 25 microg/mL for free polysaccharides, roughly a 47% dose reduction. The apoptotic mechanism involved ROS generation, Fas/APO-1 expression, mitochondrial membrane potential disruption, and activation of caspases-3, -8, and -9.

Chen et al. (2023) identified new cytotoxic metabolites from fermented Antrodia mycelium, including the novel compound antroquinonol Z.^[10] Antrocamols LT1 and LT3 at 10 microM reduced HepG2 and Huh-7 cell viability to approximately 60% within 48 hours. Partially purified fractions showed stronger cytotoxicity than individual isolated compounds, suggesting synergistic effects between multiple Antrodia metabolites.

What the Evidence Does Not Show

The HCC research on Antrodia is mechanistically rich but clinically immature. Several critical gaps limit any translation toward treatment:

No human clinical data exist. Every study reviewed here used cell lines, mouse xenografts, or syngeneic tumor models. No Phase I safety trial, much less an efficacy trial, has been conducted for Antrodia in liver cancer patients.

Cell line models have inherent limitations. HepG2, Hep3B, Huh7, and SMMC-7721 are commonly used HCC lines, but they do not capture the full heterogeneity of human liver tumors, tumor microenvironment complexity, or immune system interactions.

In vivo studies used short treatment windows. The longest in vivo study (Zhu et al., 2018) treated mice for 18 days. HCC is a chronic disease often diagnosed at advanced stages; short-term mouse data cannot predict long-term efficacy or resistance development.

Dosing translation is unclear. The effective doses in mouse models (e.g., 100 mg/kg oral EEAC) do not translate directly to human doses. Pharmacokinetic studies determining Antrodia compound bioavailability, distribution, and metabolism in humans have not been published.

No comparison to standard-of-care. While Wu et al. (2018) showed Antrodia enhanced sorafenib, no study has compared Antrodia alone to established HCC therapies. The combination data are promising but preliminary.

For a look at how Antrodia protects healthy liver tissue (rather than killing cancer cells), see how Antrodia protects liver cells: mechanisms of hepatoprotection and Antrodia and alcohol-related liver damage: research review.

The Bottom Line

Antrodia camphorata produces multiple compound classes with demonstrated activity against hepatocellular carcinoma cells in laboratory studies. Triterpenoids trigger ROS-dependent apoptosis through both intrinsic and extrinsic pathways; mycelia extracts suppress JAK2/STAT3 oncogenic signaling; ubiquinone derivatives enhance immune recognition of cancer stem cells; and combination approaches sensitize HCC cells to lower doses of sorafenib, cisplatin, and doxorubicin. The in vivo data from mouse xenograft models support the cell culture findings. The evidence is entirely preclinical. No human clinical trials have been conducted, and the translation from mouse models to human cancer treatment remains an open question.

Frequently Asked Questions

Can Antrodia camphorata treat liver cancer?

No human clinical trials have tested Antrodia for liver cancer treatment. Preclinical studies show multiple Antrodia compounds kill hepatocellular carcinoma cells in laboratory settings and reduce tumor growth in mouse models (Zhu et al., 2018; Wu et al., 2018). The compound methyl antcinate A selectively killed cancer cells while sparing normal hepatocytes (Hsieh et al., 2010). These are laboratory findings only; they do not establish Antrodia as a treatment for liver cancer in humans.

What Antrodia compounds kill liver cancer cells?

At least six compound classes from Antrodia have shown cytotoxicity against HCC cell lines. Triterpenoids methyl antcinate A and antcin B trigger apoptosis through oxidative stress and caspase activation (Hsieh et al., 2010, 2011). Antrodia polysaccharides induce apoptosis in HepG2 cells, with nanoencapsulation roughly doubling potency (Chang et al., 2015). The ubiquinone derivative 4-acetylantroquinonol B targets cancer stem cells (Li et al., 2019). Antroquinonol Z and antrocamols are newer cytotoxic metabolites (Chen et al., 2023).

Does Antrodia enhance chemotherapy for liver cancer?

Two preclinical studies suggest Antrodia extracts can sensitize HCC cells to chemotherapy drugs. Wu et al. (2018) showed Antrodia extract combined with sorafenib suppressed tumor growth in mouse xenografts beyond either agent alone. Lin et al. (2015) found Antrodia ethanolic extract enhanced the tumor suppression efficiency of cisplatin and doxorubicin in HCC cell lines. Both studies are preclinical; no human combination therapy trials have been conducted.

How does Antrodia kill liver cancer cells?

Antrodia compounds use multiple mechanisms against HCC cells. Triterpenoids activate NADPH oxidase to generate reactive oxygen species (ROS), which trigger mitochondrial membrane disruption, cytochrome c release, and caspase cascade activation (Hsieh et al., 2010). Mycelia extracts suppress the JAK2/STAT3 signaling pathway, reducing anti-apoptotic proteins and invasion-promoting enzymes (Zhu et al., 2018). Some compounds also inhibit cancer stem cell characteristics and enhance dendritic cell immune recognition (Li et al., 2019).

Is there any clinical evidence for Antrodia and liver cancer?

No. All evidence for Antrodia against hepatocellular carcinoma comes from cell culture studies and mouse tumor models. No Phase I, II, or III clinical trials have tested Antrodia for liver cancer in humans. While the preclinical data show consistent anti-HCC activity across multiple studies and compound classes, the gap between laboratory cytotoxicity and clinical cancer treatment is large and has not been bridged.

Does Antrodia camphorata target cancer stem cells?

Two studies examined Antrodia's effects on liver cancer stem cell properties. Liu et al. (2013) showed Antrodia mycelial fermentation broth inhibited angiogenesis markers, VEGF production, and HIF-1alpha expression in HCC cells. Li et al. (2019) found that 4-acetylantroquinonol B suppressed stemness markers EpCAM and AFP, reduced immune escape cytokine secretion, and enhanced dendritic cell recognition of cancer stem cells. Both studies used cell culture and mouse models only.

Sources & References

1. 1RTHM-00183·Hsieh, Yun-Chih et al. (2010). “Methyl antcinate A from Antrodia camphorata induces apoptosis in human liver cancer cells through oxidant-mediated cofilin- and Bax-triggered mitochondrial pathway..” Chemical research in toxicology.Study breakdown →PubMed →↩
2. 2RTHM-00217·Hsieh, Yun-Chih et al. (2011). “Antcin B and its ester derivative from Antrodia camphorata induce apoptosis in hepatocellular carcinoma cells involves enhancing oxidative stress coincident with activation of intrinsic and extrinsic apoptotic pathway..” Journal of agricultural and food chemistry.Study breakdown →PubMed →↩
3. 3RTHM-00540·Zhu, Pei-Li et al. (2018). “Antrodia camphorata Mycelia Exert Anti-liver Cancer Effects and Inhibit STAT3 Signaling in vitro and in vivo..” Frontiers in pharmacology.Study breakdown →PubMed →↩
4. 4RTHM-00297·Liu, Yu-Ming et al. (2013). “Medicinal Fungus Antrodia cinnamomea Inhibits Growth and Cancer Stem Cell Characteristics of Hepatocellular Carcinoma..” Evidence-based complementary and alternative medicine : eCAM.Study breakdown →PubMed →↩
5. 5RTHM-00570·Li, Ting-Yi et al. (2019). “4-Acetylantroquinonol B from antrodia cinnamomea enhances immune function of dendritic cells against liver cancer stem cells..” Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.Study breakdown →PubMed →↩
6. 6RTHM-00535·Wu, Wei-De et al. (2018). “Antrodia cinnamomea boosts the anti-tumor activity of sorafenib in xenograft models of human hepatocellular carcinoma..” Scientific reports.Study breakdown →PubMed →↩
7. 7RTHM-00393·Lin, Liang-Tzung et al. (2015). “The Ethanolic Extract of Taiwanofungus camphoratus (Antrodia camphorata) Induces Cell Cycle Arrest and Enhances Cytotoxicity of Cisplatin and Doxorubicin on Human Hepatocellular Carcinoma Cells..” BioMed research international.Study breakdown →PubMed →↩
8. 8RTHM-00080·Hsu, Ya-Ling et al. (2005). “Apoptotic effects of extract from Antrodia camphorata fruiting bodies in human hepatocellular carcinoma cell lines..” Cancer letters.Study breakdown →PubMed →↩
9. 9RTHM-00365·Chang, Jenq-Sheng et al. (2015). “Apoptosis of Hepatocellular Carcinoma Cells Induced by Nanoencapsulated Polysaccharides Extracted from Antrodia Camphorata..” PloS one.Study breakdown →PubMed →↩
10. 10RTHM-00818·Chen, Yih-Fung et al. (2023). “Chemical investigations and cytotoxic effects of metabolites from Antrodia camphorata against human hepatocellular carcinoma cells..” Natural product research.Study breakdown →PubMed →↩